Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Mead earned his medical degree from the University of Oxford and trained in hematology at St Bartholomew's Hospital and University College London. In 2007, he earned his PhD at UCL, which focused on the analysis of FLT3 mutations in acute myeloid leukemia. He is now Associate Professor of Hematology and MRC Senior Clinical Fellow at the WIMM, University of Oxford. His research group focuses on myeloid diseases and normal blood stem-cell biology. Dr Mead is the lead clinician for myeloproliferative neoplasms (MPN) and chronic myeloid leukemia in the Thames Valley Strategic Clinical Network and is the chief investigator for several chronic myeloid leukemia and MPN clinical trials. Additionally, Dr Mead has helped shape the diagnostic and treatment guidelines for MPNs in the UK and serves as the chair of the MPN clinical study subgroup of the National Cancer Research Institute.

Original publication

DOI

10.2217/fon-2017-0460

Type

Journal article

Journal

Future Oncol

Publication Date

11/2017

Volume

13

Pages

2401 - 2404

Keywords

chronic myeloid leukemia, nilotinib, treatment-free remission, Antineoplastic Agents, Clinical Trials as Topic, Fusion Proteins, bcr-abl, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Molecular Targeted Therapy, Philadelphia Chromosome, Protein Kinase Inhibitors, Pyrimidines, Remission Induction, Treatment Outcome